Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004

Acta Tropica

Volumn 100, Issue 1-2, 2006, Pages 11-16

  Likeufack, A C Lékané ^a,b   Brun, R ^c   Fomena, A ^d   Truc, P ^b  

^a Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale ^*  (Cameroon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d Université DeYaoundé i   (Cameroon)

Author keywords

Drug sensitivity; Melarsoprol; Stability in time; Trypanosoma brucei gambiense

Indexed keywords

2,5 BIS(4 AMIDINOPHENYL)FURAN; DB 289; EFLORNITHINE; MELARSENOXIDE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE ISETHIONATE; PRODRUG;

COMPARATIVE STUDY; DISEASE TREATMENT; DRUG; ISOLATED POPULATION; PARASITE; TRYPANOSOMIASIS;

AFRICA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; IC 50; IN VITRO STUDY; NONHUMAN; TRYPANOSOMA;

AFRICA, CENTRAL; AFRICA, WESTERN; ANIMALS; HUMANS; INHIBITORY CONCENTRATION 50; MELARSOPROL; PARASITIC SENSITIVITY TESTS; TIME FACTORS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

AFRICA; CENTRAL AFRICA; SUB-SAHARAN AFRICA; WEST AFRICA;

TRYPANOSOMA BRUCEI GAMBIENSE;

EID: 33751503409     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2006.09.003     Document Type: Article

References (22)

1. Bacchi C.J., Nathan H.C., Livingstone T., Valladares G., Muhamed Saric S., Sayer P.D., Njogu A.R., and Clarkson A.B.J.R. Differential susceptibility to DL-α-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob. Agents Chemother. 34 6 (1990) 1183-1188
2. Baltz T., Baltz D., Giroud C., and Crockett J. Cultivation in a semi-defined medium of animal infective forms of T. brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 4 5 (1985) 1273-1277
3. Barrett M.P. Problems for the chemotherapy of human African trypanosomiasis. Curr. Opin. Infect. Dis. 13 (2000) 647-651
4. Bouteille B., Oukem O., Bisser S., and Dumas M. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 17 (2003) 171-181
5. Brun R., Baeriswyl S., and Kunz C. In vitro drug sensitivity of Trypanosoma gambiense isolates. Acta Trop. 46 5-6 (1989) 369-376
6. Brun R., Schumacher R., Schmid C., Kunz C., and Burri C. The phenomenon of treatment failures in human African trypanosomiasis. Trop. Med. Int. Health 6 2 (2001) 906-914
7. Burri C., Baltz T., Giroud C., Doua F., Welker H.A., and Brun R. Pharmacokinetic properties of the trypanocydal drug melarsoprol. Chemotherapy 39 4 (1993) 225-234
8. Holmes P.H., Eisler M.C., and Geerts S. Current chemotherapy of animal trypanosomiasis. In: Maudlin I., Holmes P.H., and Miles M.A. (Eds). The Trypanosomiases (2004), CABI Publishing, Wallingford, UK 431-444
9. Huber W., and Koella J.C. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 55 (1993) 257-261
10. Iten M., Matovu E., Brun R., and Kaminsky R. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-α-difluoromethylornithine. Trop. Med. Parasitol. 46 (1995) 190-194
11. Keiser J., Ericsson O., and Burri C. Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin. Pharmacol. Ther. 67 5 (2000) 478-488
12. Lanham S.M., and Godfrey D.G. Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp. Parasitol. 28 (1970) 521-534
13. Legros D., Fournier C., Gastellu Etchegorry M., Maiso F., and Szumilin E. Therapeutic failure of melarsoprol among patients treated for late stage T. b. gambiense human African trypanosomiasis in Uganda. Bull. Soc. Pathol. Exot. 92 3 (1999) 171-172
14. Lekane Likeufack C., Kohagne Tongue L., and Truc P. In vitro activity of commercial formulation and active principle of trypanocidal drugs against bloodstream forms of Trypanosoma brucei gambiense. Afr. J. Biotechnol. 2 11 (2003) 474-476
15. Mäser P., Sütterlin C., Kralli A., and Kaminsky R. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285 (1999) 242-244
16. Matovu E., Enyaru J.C.K., Legros D., Schmid C., Seeback T., and Kaminsky R. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop. Med. Int. Health 6 5 (2001) 407-411
17. Morel C. Neglected diseases: under-funded research and inadequate health interventions. Can we change this reality?. EMBO Rep. 4 special issue (2003) 35-38
18. Schmid C., Brun R., Matovu E., and Legros D. Melarsoprol unresponsiveness in T. b. gambiense: evidence from in vitro drug sensitivities and patient's drug levels. Trypanosomiasis and Leishmaniasis Seminars and 3rd COST-B9 Meeting on Anti-Protozoal Chemotherapy. Bruges, Belgium (2000)
19. Stanghellini A., and Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop. Med. Int. Health 6 (2001) 330-334
20. Sturk L.M., Brock J.L., Bagnell C.R., Hall J.E., and Tidwell R.R. Distribution and quantitation of the antitrypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. Acta Trop. 91 (2004) 131-143
21. Truc P., Lekane Likeufack C., Mbongo N., and Ebo'o Enyenga V. A procedure for isolating and freezing metacyclic Trypanosoma brucei gambiense forms in the field. Acta Trop. 90 (2004) 219-221
22. World Health Organization. Control and surveillance of African trypanosomiasis. WHO Technical Series 881 (1998) 113 p.